324 South Hyde Park Avenue Suite 350
Tampa, FL 33606
Incubator: No
Founding Date: 2002
E-Florida Region: Tampa Bay
Ownership: OTC-ABPIQ.PK
Accentia BioPharmaceuticals (including subsidiaries Biovest International and TEAMM Pharma) is focused on the commercialization of "targeted" therapeutics in patent-protected drug delivery technologies related to respiratory, oncology and critical care.
Therapeutics
Targeted therapeutics--synthetic chemicals, biologics-- nucleotides, peptides, cytokines, monoclonal antibodies, or cells which restrict their action to specific cellular targets.
Targeted Rx for respiratory, CNS and oncology (BiovaxID--Phase III for Non-Hodgkins Lymphoma); SinuNase--an amphotericin B suspension.
Respi-TANN is an antitussive/decongestant combination product that is available in two presentations: Respi-TANN suspension and Respi-TANN chewable tablets.
Private placement-unknown investor; Rodman & Renshaw, LLC (New York, NY); Laurus Capital Management (New York, NY)
The University of Florida and any third party content providers shall retain all worldwide rights in the intellectual property of this site including the copyright in and to its original content. You may reproduce the site content for any legal purpose with proper attribution. Attribution shall take the following form: "Materials provided by University of Florida's Sid Martin Biotechnology Incubator www.biotech.ufl.org".